Journal article
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes
Abstract
INTRODUCTION: Recombinant factors VIII and IX Fc (rFVIIIFc/rFIXFc) became available in Canada in 2016 and were the only extended half-life (EHL) factor concentrates available in Canada until 2018.
OBJECTIVES: We aim to describe the change in product utilization in Canadians who switched to rFVIIIFc/rFIXFc.
Authors
Sun H; Yang M; Poon M; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M
Journal
Haemophilia, Vol. 27, No. 5, pp. 751–759
Publisher
Wiley
Publication Date
September 2021
DOI
10.1111/hae.14369
ISSN
1351-8216